Abstract: Objective：To analyze the effect of FBXO31 (F-box only protein 31) on the proliferation of human cervical cancer cell C-33a and the correlation between its expression in human cervical cancer tissues and clinical factors, and to explore its role in the progression of human cervical cancer in order to find new molecular targets. Methods：MTT method was used to detect the inhibition rate of C-33A cells under the action of FBXO31 at different concentration and time. The expression of FBXO31 in cervical cancer tissues and adjacent tissues of 70 patients were detected by immunohistochemistry and Western blotting, and the relationship between FBXO31 expression and clinical pathological features was analyzed. Results：MTT method showed that the proliferation of C-33A cells was inhibited by FBXO31, and the proliferation inhibition rate showed a concentration and time-dependent. Immunohistochemistry showed that FBXO31 was mainly expressed in the nucleus. The positive expression rate of FBXO31 in cervical cancer tissues (17/70, 24.29%) was significantly lower than that in the adjacent tissues (60/70, 85.71%) ( χ2=74.035, P＜0.001). Western blotting showed that the expression of FBXO31 in human cervical cancer tissues was obviously lower than that in adjacent tissues, with statistically significant difference (P＜0.05). Further analysis showed that the expression of FBXO31 in cervical cancer tissues was not related to age, tumor size and pathological type, but to FIGO stage, tumor differentiation degree, lymph node metastasis and distant metastasis (P＜0.05). Conclusions：FBXO31 may inhibit the proliferation of human cervical cancer C-33A cells as a tumor suppressor gene in a time and concentration dependent manner. It has low expression in human cervical cancer tissues and is closely related to the clinical characteristics of cervical cancer, which may be a new molecular target for cervical cancer treatment.

Key words: Uterine cervical neoplasms；, Cell proliferation；, Immunohistochemistry；, Survival analysis；, FBXO31